Purpose: The objectives of this study is to report the oncologic outcomes and safety and tolerability of induction chemotherapy in locally advanced nasopharyngeal carcinoma treated at our institution -The Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines Patients and Methods: Thirty-eight patients who underwent induction chemotherapy prior to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma at our institution were retrospectively reviewed. Of these, 14 patients were excluded (5 patients had M1 disease at diagnosis, 5 patients received induction chemotherapy (IC) for recurrent disease, 4 patients had incomplete medical records) and 24 patients were included in the i nal outcomes and safety analysis.
INTRODUCTION
Nasopharyngeal carcinoma (NPC) is unique compared to other head and neck cancers in terms of histology and epidemiology with the highest incidences reported in southeast Asia, Micronesia and Polynesia, eastern Asia, and northern Africa. [1] Because of its anatomical location and sensitivity to radiation, radiotherapy is the primary treatment modality for localized NPC. Most cases, as high as 70%, of newly diagnosed NPC are classii ed as loco-regionally advanced disease. [2] The value of adding chemotherapy was i rst shown by the landmark Intergroup 0099 study, also known as Al-Sarraf protocol. The trial showed that concurrent chemoradiotherapy with adjuvant chemotherapy provided a 31% increase in 3-year OS. Since 1998, this regimen has been deemed the standard of care for advanced NPC. [3] Since the Intergroup study, other randomized studies were conducted to coni rm the role of concurrent chemoradiotherapy with adjuvant chemotherapy (CCRT + AC) of NPC in the endemic region. [4] [5] [6] . A promising strategy to further improve the treatment outcome is to alter the sequence from concurrent-adjuvant to induction-concurrent because of several potential and theoretical advantages: 1) The early use of potent combination chemotherapy drugs at full dose allows better drug delivery through a vasculature that has not been disrupted by prior RT and is effective towards eradicating micrometastases; 2) Better tolerance of induction chemotherapy compared to adjuvant chemotherapy, taking into account the poor compliance of adjuvant chemotherapy of the Al-Sarraf regimen, which is as low as 60% [7] ; 3) Upfront chemotherapy can shrink the primary tumor to allow a wider margin for subsequent irradiation in patients with extensive locoregional disease near-critical neurological structures. [8] . However, in previous phase 3 studies that compared IC plus radiotherapy versus radiotherapy alone, IC did not reduce distant metastasis or prolong survival; one explanation is that a truly effective IC regimen has not yet been identii ed. [9] [10] [11] [12] Several randomized studies have reported promising results of IC with concurrent chemoradiotherapy (IC + CCRT) compared with CCRT alone. A phase II study of 65 patients in Hong Kong were randomized to IC with docetaxel and cisplatin for two cycles followed by concurrent chemoradiother-apy with weekly cisplatin versus concurrent chemoradiotherapy alone. Results showed manageable toxicity with no signii cant differences in the rates of acute toxicities and comparable dose intensities of concurrent cisplatin, late RT toxicities, and quality of life scores. It also showed improvement in 3-year OS (94.1% vs 67.7%).
A European phase II study was conducted by the Hellenic Cooperative Oncology Group which used cisplatin, epirubicin, and paclitaxel as induction regimen. A total of 141 patients were randomized to either IC + CCRT versus CCRT alone. The study showed similar overall response rate, 3-year PFS and OS with a manageable toxicity proi le. [14] The Hong Kong Nasopharyngeal Cancer Study Group conducted a randomized, multicenter phase 3 trial evaluating several promising strategies including changing from adjuvant to IC using cisplatin and 5FU. Induction cisplatin + 5FU (PF) did not show signii cant improvement in PFS and OS compared to adjuvant PF. The safety proi le showed fewer neutropenia and electrolyte disturbances in the induction PF arm.
In another study conducted in Singapore, the combination of gemcitabine, carboplatin, and paclitaxel was used as IC prior to CCRT. A total of 180 patients were randomized to IC + CCRT versus CCRT alone without AC. The results showed no signii cant difference in OS, disease-free survival, and distant metastasis-free survival. The induction arm showed higher rates of grade 3 and 4 leukopenia and neutropenia, but with comparable acute radiation toxicities and global quality of life scores. [16] A randomized phase III study was done in China comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus chemoradiotherapy alone in stage III and IVB NPC. The induction arm used cisplatin and 5FU every 3 weeks for two cycles. A total of 476 patients were randomized and results showed higher 3-year disease-free survival (DFS) of 82.0% versus 74.1% with marginal improvement in 3-year distant metastasis-free survival (DMFS) of 86.0% versus 82.0%. No improvement was seen in OS or LRRFS. The induction arm also had signii cantly more grade 3-4 toxicities during the CCRT. [17] In another phase III study done in China, the docetaxel/cisplatin/5FU (TPF) regimen was investigated as an induction regimen in locally advanced NPC compared to CCRT alone. A total of 239 pa-tients were randomly assigned to each treatment arm. The results showed that the addition of induction TPF to concurrent chemoradiotherapy signiicantly improved 3-year failure-free survival (80% vs 72%) with acceptable toxicity. A long-term outcome is still not reported. [18] A retrospective study was also done in Sun Yatsen University Cancer Center in China evaluating the long-term outcome of IC. A propensity-matched analysis was done in 318 paired patients. The 5-year OS and DFS were signii cantly improved with IC. [19] Another retrospective study was done this time in Siriraj Hospital in Thailand where NAC versus AC was compared using cisplatin + 5FU/leucovorin for a maximum of three cycles. In this cohort, 79 patients received NAC while 187 patients received AC. The results showed that 3-year and 5-year OS, LLRFS, and DMFS were not improved with NAC compared to AC. [20] A randomized trial was also done by the French group Groupe d'Oncologie Radiothérapie Tête Et Cou (GORTEC) employing IC with TPF followed by CCRT versus CCRT alone. A total of 83 patients were included in the study and results showed good compliance to the induction regimen (95% received three cycles of TPF). Toxicities were comparable in both arms, while 3-year PFS and OS were signiicantly improved in the induction arm.
A meta-analysis of six randomized controlled trials (RCTs) and i ve observational studies was done showing high-quality evidence from RCTs that IC signii cantly improved PFS and OS but was associated with more frequent AEs. The analysis also showed no divergent results between RCTs and observational studies. [22] .
In terms of local data, Dizon, et al. [23] reported a small phase II randomized study done at Philippine General Hospital. In this pilot study, 30 patients were randomized to receive IC (PF) followed by chemoradiotherapy versus standard Al-Sarraf protocol. Median PFS was 19.6 months (standard arm) versus 25.7 months (investigative arm). The 3-year PFS rates were 25% and 63%, respectively with hazard ratio 2.64 (p = 0.176). There was no signii cant difference in oncologic outcomes such as median and 3-year PFS and OS rates between the two arms. Anemia, anorexia, nausea, vomiting, and xerostomia were the most frequent grade 3 AEs reported.
The value of IC remains under investigation despite decades of research, and clear guidelines for the optimal use of IC are yet to be dei ned. Real-world data (RWD) and local experience are important in understanding and dei ning the value of IC in a specii c population. There had been no published local data (retrospective or prospective) on the safety and efi cacy of IC in locally advanced NPC.
This study aims to determine the oncologic outcomes as well as the safety and tolerability of IC in Filipinos with locally advanced NPC treated at the Benavides Cancer Institute from 2008 to 2018. As there is still no consensus on the role of IC in LA-NPC, RWD and local institutional experience are important in understanding the outcomes and safety of IC in a specii c population.
The primary objective of this study is to determine oncologic outcomes of IC in Filipinos with locally advanced NPC treated at the Benavides Cancer Institute in terms of the OS, PFS, LRFFS, and DFFS.
The secondary objective of this study is to determine the safety and tolerability of IC in Filipinos with locally advanced NPC treated at the Benavides Cancer Institute using the Common Terminology Criteria for Adverse Events (CTCAE v5.0).
METHODOLOGY
This is a retrospective and descriptive type of study reviewing the medical records of patients seen at the University of Santo Tomas Hospital -Benavides Cancer Institute from 2008 to 2018. The study population will include Filipino patients diagnosed with locally advanced NPC who underwent IC at the Benavides Cancer Institute at the University of Santo Tomas Hospital from 2008 to 2018. This will include patients from both private and clinical divisions.
The inclusion criteria include the following: a) Histologically coni rmed locally advanced NPC who underwent IC prior to dei nitive concurrent chemoradiotherapy; b) Stage II to IVB based on AJCC 7th edition; and c) Age >= 18 years. Patients with incomplete hospital records were excluded from this study.
The 
RESULTS

Study Population
Upon review of the hospital's cancer database, a total of 38 patients underwent IC prior to CCRT for locally advanced NPC at our institution from 2008 to 2018 and were retrospectively reviewed. Of these, 14 patients were excluded due to the following: 5 patients had M1 disease at diagnosis, 5 patients received IC for recurrent disease, 4 patients had incomplete medical records. Twenty-four patients were included in the i nal outcomes and safety analysis ( Figure 1) . Table 1 shows the baseline characteristics of the included patients. The majority were males (66.7%) with a median age of 49, all have good performance status prior to treatment with an ECOG score of 0 or 1, and mostly non-smokers (66.7%). In terms of histology and staging, the majority are of the WHO type 3 undifferentiated type (79.2%), AJCC 7 th stage IVb (62.5%), T4 (70.8%), and N3 (58.3%). Most of the patients underwent conventional radiotherapy (66.7%) rather than IMRT (33.3%). The most common IC protocol used was the PF regimen (70.8%). A taxane containing regimen (TPF or modii cation) was used in about 29.2%. Figure 2 shows the Kaplan-Meier estimate of the OS of patients who underwent IC prior to CCRT. With a median follow-up of 39 months (range 5 to 129 months), the median OS is not reached. The 1-year, 2-year, and 3-year OS rates are 91.67%, 74.77%, and 60.75%, respectively. Figure 3 shows the Kaplan-Meier estimate of PFS of patients who underwent IC followed by CCRT. The median PFS is not reached with a 1-year, 2-year, and
ONCOLOGIC OUTCOMES
3-year PFS rates of 77.78%, 57.93%, and 57.93%, respectively.
In terms of locoregional failure, 11 out of 24 patients had a locoregional failure (45.83%). Figure 4 shows the Kaplan-Meier estimate of LRFFS. The median LRFS is not reached with a 1-year, 2-year, and 3-year LRFFS rates of 70.83%, 52.96%, and 52.96%, respectively.
In terms of distant failure, only 4 out of 24 had a distant failure (16.67%). Figure 5 shows the Kaplan-Meier estimate of the DFFS of the cohort. The estimated median DFFS is not reached with 1-year, 2-year, and 3-year DFFS rates of 85.71%, 80.67%, and 80.67%, respectively. Table 3 shows the summary of oncologic outcomes for the entire cohort. Table 3 showed the most common AEs that were reported during the induction phase and CCRT phase. The most common AEs are as follows: Anemia (62.5% all grades, 4.2% grade 3 or higher); nausea/vomiting (45.8% all grades, 0% grade 3 or higher); and mucositis (33.3% all grades, 12.5% grade 3 or higher). An increase in creatinine was reported in 16.7%, all grade 1 or 2. Other electrolyte abnormalities reported were hyponatremia (12.5%), hypokalemia (8.3%), and hypomagnesemia (4.2%); all were grade 1 or 2. There were very few reported AEs of neutropenia (4.2% all grades) and there was no reported case of febrile neutropenia.
Safety and Tolerability
In terms of tolerability, Table 4 shows the median number of completed cycles and mean total cisplatin dose received during the IC and CCRT phases. A majority of patients were able to complete three or more cycles of IC (21 out of 24 or 87.5%) with a 
DISCUSSION
Based on this data set, IC as the initial treatment strategy for locally advanced NPC is associated with less favorable oncologic outcomes as compared with historical control. In the landmark Intergroup Study 0099, the median OS of the chemoradiotherapy group was not reached while the 3-year OS rate was 76%. The median PFS in the intergroup study was also not reached in the chemoradiotherapy group while the 3-year PFS rate was 69%. [3] In the updated MAC-NPC meta-analysis (Blanchard, et al., Lancet Oncology 2015) , the reported outcomes in the standard concurrent chemoradiotherapy with adjuvant chemotherapy showed OS rates at 2-year, 5-year, and 10-year of 86.6%, 70.5%, and 57.0% respectively. The meta-analysis also reported PFS rates at 2-year, 5-year, and 10-year of 77.7%, 62.2%, and 53.2%, respectively. Comparing our results with published IC studies also showed less favorable oncologic outcomes. In the study of Ying Sun, et al. in which they enrolled only stage III and IV locally advanced NPCA, [18] they reported a 3-year failure-free survival was 80% 3-year OS of 92% in the IC group using the TPF protocol. However, our result showed more favorable oncologic outcomes if we compare it with the only published local data by Dizon, et al. [24] . In that study, the median OS and PFS were 21.5 and 25.7 months, respectively while the 3-year OS and PFS rates were 25.4% and 63%, respectively. Table 5 shows the oncologic outcomes of previously published studies on IC and as compared to the current study.
Multiple factors may contribute to these inferior oncologic outcomes. In the current study cohort, all included patients are at least stage III and 87.5% are stage IV, which makes this a cohort of very advanced disease and therefore poorer oncologic outcome is expected. Furthermore, only 29.2% used a taxane containing IC regimen in the current cohort. As seen in the study by Sun Y, et al., the use of taxane containing IC regimen resulted in improved failure-free survival compared to non-taxane containing chemotherapy protocol. [18] Another possible factor that could contribute to the less favorable oncologic outcomes is the infrequent use of more advanced radiotherapy techniques such as IMRT. In this cohort, the majority used conventional RT (70.8%) and only 29.2% used IMRT. Although the advantage of IMRT is its improved safety and less toxicity compared to conventional RT, some studies showed improved oncologic outcomes with IMRT use, specii cally in locally advanced NPC. A Korean study showed improved survival (OS and PFS) in NPC using 3D and IMRT techniques compared to 2D techniques, particularly in T3 and T4 tumors. [24] In terms of patterns of failure, our results were consistent with most studies showing very few distant failures with the use of IC strategy. In this data set, only 4 out of 24 patients had distant failure (16.67%) while 11 out of 24 patients had locoregional failure (45.83%). In the Chinese study by Sun Y, et al., [18] IC signii cantly improved DFFS (90% vs 83% at 3-years, p = 0.031) but not LRFFS.
In terms of safety, the IC strategy appears to be safe as shown by very few reported AEs in all grades and most especially in grade 3 or higher. In the current study, the increase in creatinine is only observed in 16.7%, all of which were grade 1 or 2. Also, there are very few reported events of neutropenia (4.2%) and no documented report of febrile neutropenia. It is important to note that this being a retrospective study is prone to recall bias and under-reporting of AEs. In the study of Sun Y, et al., [18] 43% had grade 3 or 4 AEs, the majority of which were hematologic such as neutropenia and leukopenia.
Tolerability of IC was also appreciated in terms of the number of completed cycles both in the induction phase and concurrent chemoradiotherapy phase. The majority of patients were able to complete three or more cycles of IC (21 out of 24 or 87.5%) and the majority completed at least two cycles of cisplatin concurrent with radiotherapy (17 out of 24 or 70.8%). In the original Al-Sarraf study, [3] only 63% of patients received the three courses of concurrent chemoradiotherapy and only 55% received all three courses of adjuvant chemotherapy. In the study of Sun Y, et al., [18] 88% completed three cycles of induction TPF while only 30% completed three cycles of concurrent chemoradiotherapy.
CONCLUSION AND RECOMMENDATION
In this cohort of Filipinos with locally advanced NPC, IC strategy appears to be safe and tolerable. Oncologic outcomes were less favorable compared to the published report possibly due to very advanced disease, less use of taxane containing regimen in this cohort, less use of advanced RT technique such as IMRT, and small sample size. Nevertheless, this report of our experience is an important step in determining the applicability of IC strategy in the local setting and in Filipinos in general. Due to the small sample size of this cohort, it is recommended to combine this data with other institutions or a national database. Furthermore, a prospective trial is recommended to better understand the role of IC in our local setting.
